
Emtora Biosciences, a life science company, develops and commercializes eRapa, a novel prostate cancer drug that also slows aging.
Emtora Biosciences, founded with the mission to revolutionize cancer treatment and aging, focuses on developing and commercializing eRapa™, a novel formulation of rapamycin. This life science company aims to prevent the onset and recurrence of cancer, particularly prostate cancer, while also addressing age-related diseases. Their flagship product, eRapa™, is designed to extend healthspan and lifespan by delaying aging processes and treating early-stage cancers or precancerous conditions.
Notable affiliated individuals and investors include key figures in the biotech and pharmaceutical industries, though specific names are not provided. Emtora Biosciences has achieved significant milestones, such as demonstrating eRapa™'s efficacy in increasing healthspan and lifespan in rodent models, which has been recognized in prestigious journals like Science and Nature. The company's innovative approach has the potential to make a substantial impact on cancer treatment and aging, positioning it as a promising player in the life sciences sector.
Emtora Biosciences' most recent funding round was for $16.9M (USD) in August 2022.
As of Aug 19, 2022, Emtora Biosciences has disclosed funding of $23.8M (USD).

Retro Biosciences
retro.bio

Empiri
empiricancer.com

Ernest Pharmaceuticals
ernestpharma.com

Yiviva
yiviva.com

Cambrian BioPharma
cambrianbio.com

Remedy Plan
remedyplan.com

Etira
etira.life

Rejuveron Life Sciences
rejuveron.com

Rubedo Life Sciences
rubedolife.com

Panacela Labs
panacelalabs.com

Revere Pharmaceuticals
reverepharma.com

Eureka Therapeutics

Ora Biomedical
orabiomedical.com

Regenerative Bio
regen-bio.us

EmitBio
emitbio.com

Oisin Biotechnologies
oisinbio.com

Telo Therapeutics

Avetabiomics
avetabiomics.com

Rapalogix Health
rapalogix.com

Immuneering
immuneering.com